Stock listing
Frankfurt:4VF SinoMab Bioscience Ltd. Aktie
German listing (Frankfurt) of SinoMab Bioscience Ltd. · home listing HKEX:3681
Follow SinoMab Bioscience Ltd. into a list and get an email when it puts out news.
Home listing price · HKEX:3681
$0.94 HKD 0.00 (0.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, HKEX:3681
- Day range
- $0.92 – $0.945 HKDNov 20, 2026
- Volume
- 699,900 sharesNov 20, 2026
- Market cap
- $1.30B HKDAt the close on Nov 20, 2026 · price × 1.39B shares outstanding
- 52-week range
- $0.92 – $2.19 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $741,009 HKDMedian day 459,150 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:3681 · Home | $0.94 HKD | 0.00 (0.0%) | 699,900 | $0.94 | $0.945 | $0.92 | $0.94 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:3681 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.94 | 0.00 | 0.0% | $0.94 | $0.945 | $0.92 | 699,900 | |
| $0.94 | -0.055 | -5.5% | $1.00 | $1.01 | $0.94 | 89,100 | |
| $0.995 | +0.035 | +3.6% | $0.95 | $0.995 | $0.94 | 381,000 | |
| $0.96 | +0.005 | +0.5% | $0.955 | $1.00 | $0.955 | 461,700 | |
| $0.955 | -0.045 | -4.5% | $1.00 | $1.00 | $0.955 | 384,900 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.03 | $0.985 | 456,600 | |
| $1.00 | -0.02 | -2.0% | $1.00 | $1.01 | $0.99 | 47,700 | |
| $1.02 | +0.03 | +3.0% | $1.03 | $1.03 | $1.02 | 600 | |
| $0.99 | -0.01 | -1.0% | $0.98 | $1.00 | $0.98 | 200,100 | |
| $1.00 | -0.01 | -1.0% | $1.01 | $1.01 | $0.985 | 233,400 | |
| $1.01 | -0.015 | -1.5% | $1.005 | $1.055 | $0.995 | 2,247,000 | |
| $1.025 | +0.025 | +2.5% | $1.00 | $1.025 | $1.00 | 392,400 | |
| $1.00 | -0.015 | -1.5% | $1.005 | $1.015 | $0.965 | 1,961,700 | |
| $1.015 | -0.055 | -5.1% | $1.03 | $1.05 | $1.005 | 590,400 | |
| $1.07 | +0.05 | +4.9% | $1.005 | $1.07 | $1.00 | 342,300 | |
| $1.02 | -0.05 | -4.7% | $1.05 | $1.05 | $1.01 | 359,700 | |
| $1.07 | +0.05 | +4.9% | $1.025 | $1.075 | $1.025 | 213,900 | |
| $1.02 | -0.03 | -2.9% | $1.05 | $1.06 | $1.02 | 208,500 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.06 | $1.04 | 262,500 | |
| $1.05 | -0.065 | -5.8% | $1.055 | $1.055 | $1.015 | 561,900 | |
| $1.115 | +0.04 | +3.7% | $1.075 | $1.115 | $1.03 | 216,600 | |
| $1.075 | -0.005 | -0.5% | $1.075 | $1.08 | $1.07 | 127,500 | |
| $1.08 | -0.02 | -1.8% | $1.10 | $1.10 | $1.08 | 69,900 | |
| $1.10 | -0.07 | -6.0% | $1.155 | $1.155 | $1.05 | 660,600 | |
| $1.17 | +0.065 | +5.9% | $1.105 | $1.17 | $1.065 | 647,100 | |
| $1.105 | +0.005 | +0.5% | $1.115 | $1.22 | $1.095 | 1,079,400 | |
| $1.10 | -0.05 | -4.3% | $1.13 | $1.14 | $1.09 | 984,300 | |
| $1.15 | 0.00 | 0.0% | $1.15 | $1.24 | $1.125 | 1,852,200 | |
| $1.15 | +0.08 | +7.5% | $1.10 | $1.15 | $1.095 | 1,372,200 | |
| $1.07 | +0.015 | +1.4% | $1.05 | $1.13 | $1.04 | 1,660,500 | |
| $1.055 | +0.01 | +1.0% | $1.05 | $1.06 | $1.03 | 573,300 | |
| $1.045 | +0.03 | +3.0% | $1.00 | $1.05 | $1.00 | 83,700 | |
| $1.015 | +0.005 | +0.5% | $1.00 | $1.05 | $1.00 | 275,100 | |
| $1.01 | +0.01 | +1.0% | $1.00 | $1.02 | $0.975 | 329,700 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.03 | $0.985 | 794,100 | |
| $1.00 | -0.02 | -2.0% | $1.00 | $1.02 | $0.99 | 666,300 | |
| $1.02 | +0.02 | +2.0% | $1.00 | $1.02 | $0.96 | 1,404,900 | |
| $1.00 | -0.05 | -4.8% | $1.055 | $1.065 | $1.00 | 2,837,100 | |
| $1.05 | -0.045 | -4.1% | $1.095 | $1.11 | $1.04 | 829,200 | |
| $1.095 | -0.015 | -1.4% | $1.11 | $1.11 | $1.08 | 83,400 | |
| $1.11 | -0.005 | -0.4% | $1.11 | $1.11 | $1.065 | 349,800 | |
| $1.115 | -0.01 | -0.9% | $1.145 | $1.145 | $1.10 | 515,700 | |
| $1.125 | -0.025 | -2.2% | $1.15 | $1.15 | $1.10 | 299,100 | |
| $1.15 | +0.02 | +1.8% | $1.12 | $1.15 | $1.105 | 381,000 | |
| $1.13 | +0.025 | +2.3% | $1.115 | $1.145 | $1.085 | 1,151,100 | |
| $1.105 | +0.005 | +0.5% | $1.10 | $1.12 | $1.065 | 739,500 | |
| $1.10 | 0.00 | 0.0% | $1.10 | $1.125 | $1.08 | 328,200 | |
| $1.10 | +0.02 | +1.9% | $1.085 | $1.135 | $1.075 | 402,900 | |
| $1.08 | -0.04 | -3.6% | $1.115 | $1.115 | $1.075 | 325,200 | |
| $1.12 | 0.00 | 0.0% | $1.10 | $1.14 | $1.10 | 637,500 | |
| $1.12 | -0.025 | -2.2% | $1.125 | $1.15 | $1.115 | 548,400 | |
| $1.145 | -0.005 | -0.4% | $1.10 | $1.155 | $1.10 | 294,900 | |
| $1.15 | +0.01 | +0.9% | $1.14 | $1.16 | $1.12 | 146,700 | |
| $1.14 | +0.04 | +3.6% | $1.08 | $1.145 | $1.065 | 705,600 | |
| $1.10 | +0.025 | +2.3% | $1.075 | $1.11 | $1.06 | 176,400 | |
| $1.075 | -0.025 | -2.3% | $1.08 | $1.11 | $1.075 | 2,555,700 | |
| $1.10 | +0.025 | +2.3% | $1.075 | $1.12 | $1.03 | 666,000 | |
| $1.075 | -0.015 | -1.4% | $1.105 | $1.105 | $1.06 | 1,237,800 | |
| $1.09 | -0.02 | -1.8% | $1.09 | $1.095 | $1.05 | 1,019,100 | |
| $1.11 | +0.01 | +0.9% | $1.10 | $1.15 | $1.10 | 248,400 | |
| $1.10 | -0.01 | -0.9% | $1.11 | $1.125 | $1.08 | 126,300 | |
| $1.11 | -0.01 | -0.9% | $1.12 | $1.135 | $1.05 | 1,076,700 | |
| $1.12 | -0.08 | -6.7% | $1.19 | $1.20 | $1.09 | 2,924,700 | |
| $1.20 | -0.02 | -1.6% | $1.245 | $1.25 | $1.17 | 781,200 |
- Ticker
- Frankfurt:4VF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 5, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Latest news
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Nov 5, 2026
Closed $1.00 (-1.0%) on Nov 6, 2026
Completion of major transaction in relation to the disposal of suzhou property and facility
Nov 4, 2026
Closed $1.01 (-1.5%) on Nov 5, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Oct 7, 2026
Closed $1.07 (+1.4%) on Oct 8, 2026
Notification Letter to Non-registered Shareholders and Reply Form
Sep 28, 2026
Closed $1.00 (-2.0%) on Sep 29, 2026
Notification Letter to Registered Shareholders and Reply Form
Sep 28, 2026
Closed $1.00 (-2.0%) on Sep 29, 2026
Interim Report 2026
Sep 28, 2026
Closed $1.00 (-2.0%) on Sep 29, 2026
Supplemental announcement in relation to 2025 annual report
Sep 18, 2026
Closed $1.12 (-0.9%) on Sep 21, 2026
List of directors and their roles and functions
Jun 12, 2026
Closed $1.20 (-7.0%) on Jun 15, 2026
SinoMab Bioscience Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 8 in the last 12 months · 8 in all · newest Nov 5, 2026 · oldest 2026
Where SinoMab Bioscience Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:3681 中國抗體 · Home listing | HKEX | Hong Kong | HKD |
| gettex:4VF | gettex | Germany | EUR |
| LS Exchange:A2PURU | LS Exchange | Germany | EUR |
| Dusseldorf:4VF | Dusseldorf | Germany | EUR |
| Frankfurt:4VF · This page | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2PURU | Lang & Schwarz | Germany | EUR |
| Munich:4VF | Munich | Germany | EUR |
| Tradegate:4VF | Tradegate | Germany | EUR |
Valuation
Price/book 3.1× against a median of 2.1×: 7th lowest of 11 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.35B HKD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.7×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| SinoMab Bioscience Ltd. · HKEX:3681 | US$166.3M | US$172.4M | n/a | n/a | n/a | 3.1× | n/a | 0.7× | n/a |
| MediWound Ltd. · NASDAQ:MDWD | US$175.5M | US$155.9M | n/a | 15.6× | n/a | 5.5× | −235.0% | 0.3× | 0.64 |
| Nanexa AB · OMXSTO:NANEXA | US$175.1M | US$170.1M | n/a | 51.4× | n/a | 13.5× | −72.5% | 0.0× | n/a |
| Compugen Ltd. · NASDAQ:CGEN | US$174.3M | US$59.55M | 4.8× | 0.8× | n/a | 2.1× | 47.9% | 0.0× | 1.49 |
| Guangzhou Innogen Pharmaceutical Group Co Ltd Class H · HKEX:2591 | US$170.8M | US$40.22M | n/a | 2.1× | n/a | 1.2× | −259.6% | 0.2× | n/a |
| Entrada Therapeutics, Inc. · NASDAQ:TRDA | US$170.3M | US$24.60M | n/a | 6.2× | n/a | 0.9× | n/a | 0.2× | 1.43 |
| Prestige BioPharma Limited · KRX:950210 | US$165.8M | US$132.7M | n/a | 6.8× | n/a | 0.5× | −350.9% | 0.1× | n/a |
| Acepodia, Inc. · TPEX:6976 | US$162.7M | US$58.46M | n/a | 10,415× | n/a | 1.1× | n/a | 0.0× | n/a |
| TaiGen Biopharmaceuticals Holdings Limited · TPEX:4157 | US$161.1M | US$133.4M | 34.2× | 17.1× | 46.8× | 5.2× | 60.5% | 0.0× | n/a |
| ImmuneOncia Therapeutics Inc. · KRX:424870 | US$160.0M | US$90.35M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | n/a |
| Baijin Life Science Holdings Limited · HKEX:1466 | US$160.0M | US$158.1M | n/a | 13.9× | n/a | 6.8× | −42.4% | 0.1× | n/a |
| Median of the others | US$168.0M | US$111.5M | 19.5× | 13.9× | 46.8× | 2.1× | −72.5% | 0.0× | 1.43 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Aug 29, 2025 | −2.6% |
| Quarter to Mar 31, 2025 | Jun 13, 2025 · Before open | −10.2% |
| Q4 2024 | Mar 31, 2025 | −3.7% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 2.03M | 1.36M | 4.03M | 26.7M | 12.8M | 0 | 1.48M | 0 |
| Cost of revenue | 26.6M | 1.48M | 943.0K | 0 | 743.0K | 117.0K | |||
| Gross profit | -26.6M | 543.0K | 422.0K | 4.03M | 26.7M | 12.8M | 1.48M | -117.0K | |
| Research and development | 79.5M | 94.8M | 135.4M | 180.4M | 199.1M | 103.4M | 214.3M | 47.3M | 32.6M |
| Selling, general and administrative | 46.4M | 67.7M | 97.4M | 82.4M | 131.9M | 71.1M | 61.5M | 2.01M | 991.0K |
| Operating income | -124.7M | -161.4M | -229.6M | -258.9M | -305.9M | -162.7M | -273.9M | -54.8M | -39.6M |
| Depreciation and amortization | 27.3M | 29.0M | 36.1M | 28.0M | 20.7M | 10.7M | 8.49M | 5.34M | 4.92M |
| EBITDA | -97.4M | -132.3M | -193.5M | -230.9M | -285.2M | -152.0M | -265.5M | -49.5M | -34.7M |
| Interest expense | 5.38M | 8.66M | 6.58M | 31.9M | 5.82M | 2.42M | 2.34M | 3.03M | 2.96M |
| Income before tax | -102.3M | -185.1M | -243.1M | -284.2M | -288.2M | -122.6M | -276.3M | -83.6M | -51.9M |
| Income tax | 2.34M | ||||||||
| Net income | -102.3M | -185.1M | -243.1M | -284.2M | -288.2M | -122.6M | -278.6M | -83.6M | -48.0M |
| Earnings per share, basic | -0.08 | -0.17 | -0.24 | -0.29 | -0.29 | -0.12 | -0.33 | -0.08 | -0.05 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 333.7M | 61.9M | 203.7M | 345.7M | 563.0M | 810.4M | 1.20B | 41.5M | 66.1M |
| Short-term investments | 48.7M | 45.0M | 31.0M | 46.2M | 26.5M | 93.1M | 6.49M | 1.10M | 46.8M |
| Receivables | 6.09M | 259.0K | |||||||
| Current assets | 390.1M | 185.3M | 270.2M | 447.1M | 595.7M | 934.4M | 1.22B | 50.3M | 126.8M |
| Property, plant and equipment | 501.0M | 566.0M | 574.7M | 485.8M | 356.2M | 145.9M | 42.2M | 38.4M | 34.7M |
| Total assets | 908.5M | 753.1M | 847.8M | 1.01B | 1.04B | 1.13B | 1.28B | 88.8M | 161.6M |
| Current liabilities | 204.1M | 203.5M | 172.6M | 187.4M | 98.4M | 58.8M | 106.7M | 28.4M | 184.9M |
| Long-term debt | 192.1M | 306.6M | 324.8M | 238.4M | 193.8M | 55.5M | 20.3M | ||
| Total debt | 338.6M | 482.3M | 450.8M | 357.2M | 275.5M | 88.7M | 53.6M | 60.3M | 212.0M |
| Total liabilities | 400.4M | 560.2M | 552.2M | 498.8M | 361.4M | 142.5M | 152.2M | 61.4M | 212.6M |
| Shareholders' equity | 508.1M | 192.9M | 295.6M | 509.6M | 680.2M | 987.0M | 1.13B | 27.4M | -51.0M |
| Shares outstanding | 1.23B | 1.07B | 1.02B | 992.0M | 994.9M | 1.01B | 836.7M | 1.01B | 1.01B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -70.5M | -130.8M | -133.8M | -300.5M | -147.1M | -141.3M | -222.5M | -46.8M | -40.2M |
| Capital spending | -25.3M | -41.5M | -103.9M | -112.8M | -198.2M | -76.0M | -42.3M | -2.75M | -823.0K |
| Free cash flow | -95.8M | -172.3M | -237.7M | -413.3M | -345.3M | -217.3M | -264.8M | -49.6M | -41.0M |
| Cash from investing | 16.3M | -94.5M | -96.9M | -81.4M | -137.7M | -179.2M | -42.3M | 21.5M | 10.3M |
| Cash from financing | 329.4M | 73.3M | 82.3M | 102.3M | 57.5M | -18.8M | 1.42B | -3.56M | 89.0M |
| Share buybacks | 54.8M | 10.0M | 46.1M | -59.7M | 0 | 1.43B | 148.9M | 35.0K | |
| Change in cash | 260.8M | -141.8M | -139.2M | -220.1M | -247.4M | -390.5M | 1.16B | -24.6M | 57.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026 | Nov 5, 2026 | Monthly return | HKEX |
| COMPLETION OF MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF SUZHOU PROPERTY AND FACILITY | Nov 4, 2026 | Acquisition or disposal | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026 | Oct 7, 2026 | Monthly return | HKEX |
| Notification Letter to Non-registered Shareholders and Reply Form | Sep 28, 2026 | Notification letter | HKEX |
| Notification Letter to Registered Shareholders and Reply Form | Sep 28, 2026 | Notification letter | HKEX |
| Interim Report 2026 | Sep 28, 2026 | Interim report | HKEX |
| SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO 2025 ANNUAL REPORT | Sep 18, 2026 | Annual report | HKEX |
| LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | Jun 12, 2026 | List of directors | HKEX |
Cap table
Built by 6ix from SinoMab Bioscience Ltd.’s releases
- Common shares
- 1,386,638,336
- Fully diluted
- 1,386,638,336
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,386,638,336 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,386,638,336 |
Log in to ask 6ix AI your own questions about SinoMab Bioscience Ltd.